RNS Number : 0913C
Proteome Sciences PLC
30 April 2012
Proteome Sciences plc
Total Voting Rights
In accordance with the FSA's Disclosure and Transparency Rule 5.6.1, Proteome Sciences plc (the "Company") announces that the Company's issued share capital consists of 192,498,477 ordinary shares of 1 pence each ("Ordinary Shares") with voting rights. There are no Ordinary Shares held in treasury.
Therefore the total number of voting rights in Proteome Sciences plc at the date of this notice is 192,498,477.
The above figure (192,498,477) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Proteome Sciences plc under the FSA's Disclosure and Transparency Rules.
For further information please contact:
Proteome Sciences plc
www.proteomics.com Tel: +44 (0)1932 865065
Christopher Pearce, Chief Executive firstname.lastname@example.org
James Malthouse, Finance Director email@example.com
Dr. Ian Pike, Chief Operating
Nominated Adviser Tel: +44 (0)20 7397 8900
Cenkos Securities plc
Stephen Keys/Camilla Hume
Public Relations IKON Associates
FTI Consulting Adrian Shaw
Ben Atwell/Mo Noonan Tel: +44 (0)1483 271291
Tel: +44 (0)20 7269 7116 Mobile: +44 (0)7979 900733
Email: firstname.lastname@example.org Email: Adrian@ikonassociates.com
Notes to Editors:
About Proteome Sciences
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development.
Its PS Biomarker Services(TM) uses isobaric and isotopic Tandem Mass Tag(R) (TMT(R) ) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.
This information is provided by RNS
The company news service from the London Stock Exchange